
Conference Coverage
about 1 month ago
NeuroOp Guru at AAO 2026: Blurry vision in MS isn’t always a relapseabout 1 month ago
AAO 2026: Rethinking dry eye as a spectrum of ocular painabout 1 month ago
AAO 2026: Preventing complications in uveitic cataract surgeryabout 1 month ago
AAO 2026: Setting realistic expectations with refractive IOLsabout 1 month ago
AAO 2026: Comprehensive ophthalmologists are the uveitis front lineTrending on the Eye Care Network
Why ST-100 is expanding from dry eye into corneal wound healing
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
Veterinary evidence makes the case for UVC in human keratitis
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
Latest News

FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room

Q&A: GLP-1 RAs and NAION, the case for a baseline exam

Veterinary evidence makes the case for UVC in human keratitis

Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada

ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy

Shorts










Digital Edition



Podcasts
Continuing Medical Education
All News

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

A hydrophilic topical cannabidiol formulation produced a sustained, largely local IOP reduction in DBA/2J mice with chronic dosing, adding a new wrinkle to one of glaucoma’s longest-running debates.

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

The Neurolens N3 gains EU MDR certification for Contoured Prism lens prescribing, with first European launches planned for 2027.

The non-invasive device, already available in Canada, Australia, and New Zealand, delivers low-level microcurrent through closed eyelids in 32-minute in-clinic sessions.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

A structure-first approach to blepharoplasty and filler yields more durable, natural results.

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

Industry leadership gave her a wider lens that she now brings to patient care.

A systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Retinal thickness fell by more than 100 µm within 8 weeks in each case.

Two cases highlight when to start therapy in extensive and early atrophy

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.




























